STADA continues strong first-half 2024 growth

German generics major STADA Arzneimittel (SAZ: Xetra) today announced that it achieved sales of more than 2 billion euros ($2.23 billion) in the first half of 2024.

Group revenues in the six months increased by 9% to 2.02 billion euros compared to the first half of 2023, outpacing market trends, while effective investments drove reported earnings before interest, tax, depreciation and amortization (EBITDA), adjusted for currency fluctuations and special items, by 11% to 463.5 million euros.

STADA noted that the broad-based revenues and profit growth in the first half came amid a challenging macroeconomic environment of major economies stagnating and inflation persisting, albeit at a lower level than in 2023.